Absence of inhibitory effect of levocetirizine on the metabolism of human cytochrome P450 model substrates Source: Eur Respir J 2005; 26: Suppl. 49, 136s Year: 2005
The perpetrator potential of sitaxentan: human CYP enzyme induction Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008
Inhibition of human lung fibroblast functions by roflumilast N-oxide Source: Eur Respir J 2006; 28: Suppl. 50, 662s Year: 2006
Novel inhibitory effect on 5-lipoxygenase activity by montelukast. Evidence for a noncompetitive mode of action Source: Eur Respir J 2004; 24: Suppl. 48, 96s Year: 2004
Oral administration of a new prostacyclin agonist with thromboxane synthase inhibitory activity improves bleomycin-induced lung fibrosis Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010
Anti-inflammatory efficacy of formoterol via transrepressive mechanisms is independent of the glucocorticoid receptor in human bronchial epithelial cells Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Rapid inhibitory effects of budesonide and formoterol on bradykinin-induced Ca2+ mobilization in human lung fibroblasts Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010
Synergistic inhibition of oxidative burst in human eosinophils by combination treatment with formoterol and budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
‘Total PDE4 inhibitory activity‘: a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions Source: Eur Respir J 2006; 28: Suppl. 50, 436s Year: 2006
The perpetrator potential of sitaxentan based on its ability to inhibit human cytochrome P450 (CYP) enzymes Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008
No direct inhibition of NO synthases by montelukast Source: Eur Respir J 2004; 24: Suppl. 48, 578s Year: 2004
Interactions between roflumilast and cytochrome P450 inducers and inhibitors: Overview of existing studies Source: Annual Congress 2010 - Management of airway disease Year: 2010
Anti-inflammatory effects of roflumilast N-oxide and dexamethasone in human bronchial epithelial cells stimulated with toll-like receptor agonists Source: Annual Congress 2013 –The pulmonary epithelium: recent developments Year: 2013
Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 111s Year: 2007
Protective effect of leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006
In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007
Superior in vivo efficacy of macitentan: Comparison to other endothelin receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
The combination of budesonide and formoterol exerts more rapid and enhanced anti-inflammatory effects than either drug alone in rat lungs in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004
Roflumilast and its active metabolite roflumilast N-oxide do not interact with R- and S-warfarin Source: Eur Respir J 2003; 22: Suppl. 45, 103s Year: 2003
In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilastSource: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001